Increase in sales of ProSense®, based on preliminary unaudited results, demonstrate growing adoption of ProSense® cryoablation for breast tumors. FDA decision on ...

IceCure Medical’s next-generation cryoablation technology to receive European patent: Caesarea, Israel Monday, January 6, 2025, 13:00 Hrs [IST] IceCure Medical Ltd., a developer ...

IceCure Medical (Nasdaq:ICCM) announced today that it received an intention to grant notice from the European Patent Office.

IceCure Medical Ltd. (NASDAQ: ICCM) watched its shares make marginal gains Friday. The Israeli-based developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an ...

Icecure Medical ( ) has issued an update. IceCure Medical has received an Intention to Grant Notice from the European Patent Office for its innovative cryogenic system connector t ...

IceCure Medical (ICCM) announced it has received an Intention to Grant Notice from the European Patent Office, EPO, for its invention titled “Cryogenic System Connector”. This invention was ...

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

XSensetm system's innovative cryogenic connector technology designed to improve safety and maintain the integrity of cryogen used in the cryoablation procedure CAESAREA, Israel, Jan. 3 ...

XSense™ system's innovative cryogenic connector technology designed to improve safety and maintain the integrity of cryogen used in the cryoablation procedure "We are experiencing increased ...

ByInvesting.com • Oct 21, 2024 IceCure Medical Ltd Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System IceCure Medical Ltd. (Nasdaq ...